Healthcare · Pharmaceuticals & Biotechnology
QVM read Mixed signals Quality Weak, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).
Ranks #175 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 2 Apr 2024 | Sanka Satya Praveen Kumar | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Sarath Kumar | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Venkata Ratnamma | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Naga Jyothi | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Hema Kumari | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Lakshmi Sravani Dasari | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Venkata Subbamma | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Srinivas Kumar | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Ravi Sankar | Other | Sell | 0 | ₹0 |
| 2 Apr 2024 | Sanka Balaji Venkateswarlu | Other | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 8 Sep 2026 | SRINIVASARAO KARI | Bulk | Buy | 44,683 | 16.1200 | NSE |
| 10 Jul 2026 | WAVE CAPITAL LTD | Bulk | Sell | 50,000 | 16.2400 | NSE |
| 8 Jun 2026 | KUMARI ARUNIMA | Bulk | Buy | 50,000 | 19.8100 | NSE |
| 24 Feb 2026 | MIR ATA ALI KHAN | Bulk | Buy | 46,000 | 17.9700 | NSE |
| 20 Feb 2026 | VIVEK KANDA | Bulk | Buy | 50,000 | 19.8700 | NSE |
| 20 Feb 2026 | SHIVAM OMAR | Bulk | Sell | 48,798 | 19.9000 | NSE |
| 20 Feb 2026 | SHIVAM OMAR | Bulk | Buy | 9,184 | 18.6400 | NSE |
| 20 Feb 2026 | NEO APEX VENTURE LLP | Bulk | Sell | 51,773 | 19.9000 | NSE |
| 20 Feb 2026 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Buy | 17,500 | 19.9000 | NSE |
| 20 Feb 2026 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | Bulk | Sell | 43,054 | 19.8800 | NSE |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| — | NAME_CHANGE | Name changed from Ortin Laboratories Limited to ORTIN GLOBAL LIMITED |
| 22 Sep 2023 | OTHER | Annual General Meeting |
| 23 Sep 2022 | OTHER | Annual General Meeting |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 14 Aug 2026 | Financial Results/Other business matters | Yes |
| 30 May 2026 | Financial Results/Other business matters | Yes |
| 14 Feb 2026 | Financial Results/Other business matters | Yes |
| 14 Nov 2025 | Financial Results/Other business matters | Yes |
| 14 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
